Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single

Lachlan Gray1, Melissa J Churchill, Jasminka Sterjovski

  • 1Macfarlane Burnet Institute for Medical Research and Public Health, Victoria, Australia. lachlang@burnet.edu.au

Virology Journal
|July 20, 2007
PubMed

Insights

Independent env evolution in nef-deleted HIV-1 may drive disease progression in slow progressors (SP) and long-term nonprogressors (LTNP) within the Sydney blood bank cohort (SBBC). This suggests factors beyond nef influence HIV-1 pathogenicity.

Area of Science:

  • Virology
  • Immunology

Background:

  • The Sydney blood bank cohort (SBBC) comprises individuals infected with nef-deleted HIV-1.
  • This cohort includes slow progressors (SP) and long-term nonprogressors (LTNP).
  • Convergent evolution of nef sequences suggests other factors dictate HIV-1 pathogenicity.

Purpose of the Study:

  • To investigate the phenotype and env sequence diversity of nef-deleted HIV-1 variants.
  • To understand mechanisms underlying the pathogenicity of nef-deleted HIV-1 in the SBBC.

Main Methods:

  • Sequential isolation of viruses from SP and LTNP individuals.
  • Analysis of viral phenotype, including coreceptor usage (CCR5, CXCR4) and replication capacity in peripheral blood mononuclear cells (PBMC).
  • Detailed analysis of env gene evolution using V1V2 heteroduplex tracking, length polymorphism analysis, sequencing, and phylogenetic methods.

Main Results:

  • Viruses from one SP (D36) showed R5X4 tropism and low replication in PBMC.
  • Viruses from another SP (C98) and an LTNP (C18) were CCR5-restricted.
  • Distinct intra- and inter-patient evolution of the env gene was observed in all subjects.

Conclusions:

  • Independent evolution of the env gene may contribute to HIV-1 pathogenicity in the SBBC.
  • Pathogenicity is not necessarily linked to changes in viral replication capacity or coreceptor specificity.
  • These findings highlight the complex interplay of viral factors in HIV-1 disease progression.
Abstract